Table 1.

Clinicopathologic characteristics of 2 population-based prostate cancer patient cohorts

Seattle cohort (n = 1,309)Swedish cohort (n = 2,875)
N%N%
Age at diagnosis, y
 Mean59.965.8
 Median60.064.9
 Range35.0–74.044.6–80.4
Follow-up time, y
 Mean8.56.0
 Median6.56.5
 Range0.8–15.90.3–8.6
Prostate cancer-specific death
 Noa1,24995.42,37482.6
 Yes604.650117.4
Age at death, y
 Mean63.971.2
 Median65.271.2
 Range44.9–78.348.5–85.7
Stage
 Local1,02378.21,88565.6
 Regional25419.465122.6
 Distant322.42669.3
 Missing00.0732.5
Gleason score
 2–4675.11063.7
 5–668051.91,26944.1
 743233.078227.2
 8–101269.646716.2
 Missing40.32518.7
Diagnostic PSA level, ng/mL
 < 417813.61485.1
 4–9.972255.299334.5
 10–19.919114.665122.6
 ≥ 201189.01,00334.9
 Missing1007.6802.8
Primary therapy
 Radical prostatectomy77058.871324.8
 Radiation therapy35927.468223.7
 Androgen deprivation614.792732.2
 None1158.848817.0
 Other40.3220.8
 Missing00.0431.5
  • aIncludes men who died of other causes and were censored at time of death (Seattle, n = 102; Sweden, n = 258).